MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, October 1, 2014

New Findings on How Glatiramer Acetate Works for Multiple Sclerosis

By Gale Scott | September 29, 2014

 Patients with the relapsing-remitting (RRMS) form of multiple sclerosis (MS) have shown improvement with glatiramer acetate (Copaxone/Teva). But researchers are still uncertain exactly how the drug works.

In research published online Sept. 29 in Jama Neurology a University of Texas Southwestern Medical Center team in Dallas, TX, reported on the ways in which glatiramer acetate affects B cells in these patients.

Nancy Monson, PhD, and colleagues looked at cell samples from 22 patients with MS who were receiving treatment with glatiramer acetate, 22 RRMS patients who were treatment naïve, and 15 healthy controls. They found that glatiramer acetate therapy affects several aspects of dysregulated B-cell function in MS. These changes “may contribute to the therapeutic mechanisms of glatiramer acetate,” the team wrote. 

The B cells of patients with RRMS lose the ability to produce the regulatory cytokine interleukin 10. The question for the team was whether glatiramer acetate would normalize cytokine production. 

They found that the therapy affects B-cell function but that “the exact contribution of B-cell-derived cytokines in MS is not clear.” The researchers said they suspect that the drug affects the pathway of B-cell activation.

 “It stands to reason that glatiramer acetate therapy may alter pathways that are important for integrating these activation signals and other key immunologic genes that are modulated by glatiramer acetate therapy,” they wrote.

Continue reading

 Keep CURRENT and up to date, 
Sign-Up for our email

WATCH OUR Multiple Sclerosis recorded


No comments: